Grufity logoGrufity logo

Moderna Inc Stock Research

MRNA

151.78USD+2.18(+1.46%)Delayed

Market Summary

USD151.78+2.18
Delayed
1.46%

MRNA Alerts

MRNA Stock Price

MRNA RSI Chart

MRNA Valuation

Market Cap

58.4B

Price/Earnings (Trailing)

6.99

Price/Sales (Trailing)

3.03

EV/EBITDA

5.55

Price/Free Cashflow

12.76

MRNA Price/Sales (Trailing)

MRNA Profitability

EBT Margin

49.71%

Return on Equity

43.73%

Return on Assets

32.34%

Free Cashflow Yield

7.84%

MRNA Fundamentals

MRNA Revenue

Revenue (TTM)

19.3B

Revenue Y/Y

-29.5%

Revenue Q/Q

51.13%

MRNA Earnings

Earnings (TTM)

8.4B

Earnings Y/Y

-69.91%

Earnings Q/Q

40.46%

Price Action

52 Week Range

115.03217.25
(Low)(High)

Last 7 days

5.3%

Last 30 days

-12.8%

Last 90 days

-27.8%

Trailing 12 Months

1%

MRNA Financial Health

Current Ratio

2.73

MRNA Investor Care

Buy Backs (1Y)

4.47%

Diluted EPS (TTM)

20.12

Peers (Alternatives to Moderna)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
125.3B
26.3B
-2.75% 3.76%
19.12
4.76
1.32% 11.18%
99.6B
27.3B
-8.96% 41.01%
21.68
3.65
-0.09% -26.23%
58.4B
19.3B
-12.76% 1.00%
6.99
3.03
4.29% -31.47%
38.3B
10.2B
-9.67% 32.94%
12.57
3.76
-7.36% 95.80%
MID-CAP
9.1B
1.5B
-9.09% 3.35%
58.87
6.11
31.34% 72.43%
3.2B
108.5M
-21.10% -19.55%
-9.78
29.38
122.90% -12.19%
2.5B
60.9M
-18.47% -36.46%
-8.76
41.55
17.51% 22.00%
2.1B
107.9M
22.95% 67.45%
-4.29
19.27
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-14.86% -46.41%
-4.63
11.04
-70.76% -603.77%
1.1B
7.0M
-22.18% 24.65%
-7.11
158.97
131.81% -45.39%
541.9M
96.3M
-12.99% -82.24%
-1.92
5.63
72.44% -32.79%
513.7M
2.0B
-39.67% -92.01%
-0.78
0.26
72.89% 62.27%
355.3M
111.3M
-30.55% -58.78%
-1.85
3.19
0.54% -7.86%
101.4M
159.0K
-16.47% -82.96%
-0.97
637.62
-86.46% -64.56%
25.1M
-
94.03% -77.12%
-0.31
3.21
0.51% -185.61%

Financials for Moderna

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-9.9%19,26321,39022,99522,60018,471
  S&GA Expenses18.2%1,132958848758567
  R&D Expenses20.6%3,2952,7322,4332,1441,991
EBITDA-37.7%9,94815,96816,56413,531-
EBITDA Margin-25.6%0.52*0.69*0.73*0.73*-
Earnings Before Taxes-28.2%9,57513,33015,66516,25413,285
EBT Margin-20.2%0.50*0.62*0.68*0.72*-
Interest Expenses78.6%25.0014.00---
Net Income-28.9%8,36211,76514,05514,63812,202
Net Income Margin-21.1%0.43*0.55*0.61*0.65*-
Free Cahsflow-26.1%4,5816,2019,21513,031-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-0.8%25,85826,05626,04327,60924,669
  Current Assets-6.1%13,43114,29713,56316,35016,071
    Cash Equivalents5.9%3,2053,0272,8735,0486,848
  Inventory-54.3%9492,0771,9211,9421,441
Liabilities-16.5%6,7358,0648,05810,53410,524
  Current Liabilities-27.7%4,9236,8076,8129,2389,128
Shareholder's Equity6.3%19,12317,99217,98517,07514,145
  Retained Earnings8.7%18,32016,85515,81213,6159,958
  Additional Paid-In Capital-21.2%1,1731,4882,4133,6444,211
Shares Outstanding-0.5%385387392400403
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-24.9%4,9816,6299,65313,41213,620
  Share Based Compensation12.4%226201171156142
Cashflow From Investing1.7%-5,176-5,266-9,538-12,264-8,523
Cashflow From Financing11.2%-3,448-3,883-2,844-1,541-873
  Buy Backs-12.0%3,3293,7842,7781,480857

Risks for MRNA

What is the probability of a big loss on MRNA?

99.1%


Probability that Moderna stock will be more than 20% underwater in next one year

81.4%


Probability that Moderna stock will be more than 30% underwater in next one year.

49.1%


Probability that Moderna stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Moderna was unfortunately bought at previous high price.

Drawdowns

Returns for MRNA

Cumulative Returns on MRNA

91.5%


3-Year Cumulative Returns

Which funds bought or sold MRNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
4.98
674,929
1,810,930
0.05%
2023-03-13
Claro Advisors LLC
reduced
-10.03
44,165
380,165
0.12%
2023-03-10
BAILLIE GIFFORD & CO
reduced
-1.09
2,690,230,000
8,044,600,000
8.38%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
60.78
49,677,000
84,122,000
0.09%
2023-03-10
MATHER GROUP, LLC.
reduced
-8.35
334,312
1,185,310
0.02%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
new
-
265,658
265,658
0.04%
2023-03-06
Rockefeller Capital Management L.P.
added
182
16,322,000
21,280,000
0.11%
2023-03-03
TIAA, FSB
added
55.63
551,758
955,758
-%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
176,925
176,925
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
reduced
-8.13
5,297
20,297
0.01%

1–10 of 48

Latest Funds Activity

Are funds buying MRNA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own MRNA
No. of Funds

Moderna News

Investor's Business Daily

Dow Jones Near Session Highs; Will Bank Crack Leave Fed Rate ....

Investor's Business Daily,
110 minutes ago

The Motley Fool

Seeking Alpha

Schedule 13G FIlings of Moderna

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
7.10%
27,282,173
SC 13G/A
Feb 01, 2023
blackrock inc.
6.8%
26,115,224
SC 13G/A
Jan 19, 2023
baillie gifford & co
11.66%
44,786,746
SC 13G/A
Feb 14, 2022
bancel stephane
7.64%
31,538,184
SC 13G/A
Feb 14, 2022
flagship ventures fund iv general partner llc
2.8%
11,460,435
SC 13G/A
Feb 04, 2022
blackrock inc.
6.8%
27,661,473
SC 13G
Jan 26, 2022
baillie gifford & co
11.29%
45,772,079
SC 13G/A
Jul 12, 2021
blackrock inc.
4.8%
19,390,725
SC 13G/A
Mar 01, 2021
baillie gifford & co
11.18%
44,691,386
SC 13G/A
Feb 16, 2021
flagship ventures fund iv general partner llc
2.9%
11,460,435
SC 13G/A

MRNA Fair Value

Moderna fair value in different scenarios

The table shows the Fair Value estimates for Moderna for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

956.74

530.35%

1239.83

716.86%

2702.82

1680.75%

4476.90

2849.60%

7528.63

4860.23%
Current Inflation

878.54

478.82%

1122.30

639.43%

2389.70

1474.45%

3898.91

2468.79%

6493.86

4178.47%
Very High Inflation

781.19

414.69%

978.77

544.86%

2017.09

1228.96%

3222.56

2023.18%

5294.41

3388.21%

Historical Moderna Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Moderna

View All Filings
Date Filed Form Type Document
Mar 15, 2023
DEF 14A
DEF 14A
Mar 15, 2023
DEFA14A
DEFA14A
Mar 10, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading

Latest Insider Trading transactions for MRNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-09
Bancel Stephane
acquired
39,600
0.99
40,000
chief executive officer
2023-03-09
Bancel Stephane
sold
-5,567,860
139
-40,000
chief executive officer
2023-03-08
Klinger Shannon Thyme
sold
-79,387
141
-561
chief legal officer
2023-03-08
Bancel Stephane
acquired
39,600
0.99
40,000
chief executive officer
2023-03-08
Bancel Stephane
sold
-5,655,310
141
-40,000
chief executive officer
2023-03-07
Klinger Shannon Thyme
acquired
-
-
1,138
chief legal officer
2023-03-02
Bancel Stephane
acquired
39,600
0.99
40,000
chief executive officer
2023-03-02
Hoge Stephen
sold
-160,583
136
-1,177
president
2023-03-02
Bancel Stephane
sold
-5,500,040
137
-40,000
chief executive officer
2023-03-02
Klinger Shannon Thyme
sold
-62,623
136
-459
chief legal officer

1–10 of 50

Stéphane Bancel
2700
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

MRNA Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Total revenue$ 19,263$ 18,471$ 803
Operating expenses:   
Cost of sales5,4162,6178
Research and development3,2951,9911,370
Selling, general and administrative1,132567188
Total operating expenses9,8435,1751,566
Income (loss) from operations9,42013,296(763)
Interest income2001825
Other expense, net(45)(29)(6)
Income (loss) before income taxes9,57513,285(744)
Provision for income taxes1,2131,0833
Net income (loss)$ 8,362$ 12,202$ (747)
Earnings (loss) per share:   
Basic (in usd per share)$ 21.26$ 30.31$ (1.96)
Diluted (in usd per share)$ 20.12$ 28.29$ (1.96)
Weighted average common shares used in calculation of earnings (loss) per share:   
Basic (in shares)394403381
Diluted (in shares)416431381
Product sales   
Revenue:   
Total revenue$ 18,435$ 17,675$ 200
Grant revenue   
Revenue:   
Total revenue388735529
Collaboration revenue   
Revenue:   
Total revenue$ 440$ 61$ 74

MRNA Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 3,205$ 6,848
Investments6,6973,879
Accounts receivable1,3853,175
Inventory9491,441
Prepaid expenses and other current assets1,195728
Total current assets13,43116,071
Investments, non-current8,3186,843
Property, plant and equipment, net2,0181,241
Right-of-use assets, operating leases121142
Deferred tax assets982326
Other non-current assets98846
Total assets25,85824,669
Current liabilities:  
Accounts payable487302
Accrued liabilities2,1011,472
Deferred revenue2,0386,253
Income taxes payable48876
Other current liabilities249225
Total current liabilities4,9239,128
Deferred revenue, non-current673615
Operating lease liabilities, non-current92106
Financing lease liabilities, non-current912599
Other non-current liabilities13576
Total liabilities6,73510,524
Commitments and contingencies (Note 12)
Stockholders’ equity:  
Preferred stock, $0.0001; 162 shares authorized as of December 31, 2022 and 2021; no shares issued or outstanding at December 31, 2022 and 202100
Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2022 and 2021; 385 and 403 shares issued and outstanding as of December 31, 2022 and 2021, respectively00
Additional paid-in capital1,1734,211
Accumulated other comprehensive loss(370)(24)
Retained earnings18,3209,958
Total stockholders’ equity19,12314,145
Total liabilities and stockholders’ equity$ 25,858$ 24,669